Ye Zhang1, Si Zhen Li2, Lei Li1, Ming Guang He3, Ravi Thomas4, Ning Li Wang5. 1. Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology and Visual Science Key Lab, Beijing, People's Republic of China. 2. Nanjing Aier Eye Hospital, Nanjing, People's Republic of China. 3. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, People's Republic of China. 4. Queensland Eye Institute, Brisbane, Queensland, Australia University of Queensland, Brisbane, Queensland, Australia. 5. Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology and Visual Science Key Lab, Beijing, People's Republic of China Beijing Institute of Ophthalmology, Beijing, People's Republic of China.
Abstract
PURPOSE: To estimate and compare the change in iris cross-sectional area (IA) and iris volume (IV) following physiologic and pharmacologic pupil dilation in primary angle closure suspects (PACS) and normal subjects. METHODS: Anterior segment-optical coherence tomography (AS-OCT) measurements in light, dark, and following pharmacologic dilation were obtained on 186 PACS and 224 normal subjects examined during the 5-year follow-up of the Handan Eye Study. Iris cross-sectional area, IV, and other biometric parameters calculated using the Zhongshan angle assessment program in the right eyes of all subjects were analyzed. RESULTS: The mean IA and IV decreased in dark compared with light and after pharmacologic dilation in both PACS and normal eyes. This change was statistically significant in normal eyes: light versus pharmacologic dilation for IA (P = 0.038) and for IV, both light versus dark (P = 0.031) and light versus pharmacologic dilation (P = 0.012). A longer axial length (P = 0.028) and a greater change in pupil diameter (PD) (P < 0.001) were associated with a larger decrease of IA for the light to dark comparison. A diagnosis of normal eyes (P = 0.011), larger PD in dark (P = 0.001), and a larger change in PD (P = 0.001) were associated with a larger decrease of IV from light to dark. CONCLUSIONS: The differences in iris behavior between PACS and normal rural Chinese subjects following physiologic or pharmacologic pupillary dilation may help provide insights into the pathogenesis of angle closure. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
PURPOSE: To estimate and compare the change in iris cross-sectional area (IA) and iris volume (IV) following physiologic and pharmacologic pupil dilation in primary angle closure suspects (PACS) and normal subjects. METHODS: Anterior segment-optical coherence tomography (AS-OCT) measurements in light, dark, and following pharmacologic dilation were obtained on 186 PACS and 224 normal subjects examined during the 5-year follow-up of the Handan Eye Study. Iris cross-sectional area, IV, and other biometric parameters calculated using the Zhongshan angle assessment program in the right eyes of all subjects were analyzed. RESULTS: The mean IA and IV decreased in dark compared with light and after pharmacologic dilation in both PACS and normal eyes. This change was statistically significant in normal eyes: light versus pharmacologic dilation for IA (P = 0.038) and for IV, both light versus dark (P = 0.031) and light versus pharmacologic dilation (P = 0.012). A longer axial length (P = 0.028) and a greater change in pupil diameter (PD) (P < 0.001) were associated with a larger decrease of IA for the light to dark comparison. A diagnosis of normal eyes (P = 0.011), larger PD in dark (P = 0.001), and a larger change in PD (P = 0.001) were associated with a larger decrease of IV from light to dark. CONCLUSIONS: The differences in iris behavior between PACS and normal rural Chinese subjects following physiologic or pharmacologic pupillary dilation may help provide insights into the pathogenesis of angle closure. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
Authors: Lauren S Blieden; Alice Z Chuang; Laura A Baker; Nicholas P Bell; Timothy S Fuller; Kimberly A Mankiewicz; Robert M Feldman Journal: Invest Ophthalmol Vis Sci Date: 2015-05 Impact factor: 4.799
Authors: Kenneth M Marion; Jyotsna Maram; Xiaojing Pan; Anna Dastiridou; ZhouYuan Zhang; Alex Ho; Brian A Francis; Srinivas R Sadda; Vikas Chopra Journal: J Glaucoma Date: 2015-12 Impact factor: 2.503
Authors: Anna I Dastiridou; Xiaojing Pan; ZhouYuan Zhang; Kenneth M Marion; Brian A Francis; Srinivas R Sadda; Vikas Chopra Journal: J Ophthalmol Date: 2015-03-23 Impact factor: 1.909
Authors: Jeffrey R Peterson; Lauren S Blieden; Alice Z Chuang; Laura A Baker; Mohammed Rigi; Robert M Feldman; Nicholas P Bell Journal: PLoS One Date: 2016-01-27 Impact factor: 3.240